Clinical trial · Observational
SENOVIE France - Therapeutic Mobility and Breast Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Background In France, there were 61,214 new cases of breast cancer in France in 2023 with an estimated prevalence in 2017 of 913,089 people. It is thus the most common cancer in women, with an incidence that has been increasing since 1990, due both to changes in screening but more recently to a moderate increase in relation to changes in risk factors. Social inequalities in breast cancer are documented, but there are no data on immigrant women, and there is reason to believe that their trajectories may be different from those of women born in France (characteristics and age of cancer onset, problems of access to care, isolation, etc.). The SENOVIE France project aims to better understand the impact of breast cancer on the life trajectories of women born in France and women born in sub-Saharan Africa. Objectives The SENOVIE France survey aims : * To understand how breast cancer (diagnosis, treatment, and breast reconstruction) impacts women's lives that are already affected by migration in many spheres (i.e., social consequences of breast cancer on spheres like family or occupation/financial situation). * To study the therapeutic itineraries (including self-reconstruction) of immigrant women living with breast cancer in the greater Paris area and understand their social determinants. * To observe how gender can shape women's medical and social outcomes in a migration context. Methodology The SENOVIE France survey is a mixed-methods survey with a quantitative and a qualitative component. The quantitative component consists of a quantitative, retrospective, life-event survey carried out among 500 women living with breast cancer and followed in four health services in the greater Paris area. Women born in France and sub-Saharan Africa will be surveyed. This survey consists of a CAPI patient questionnaire and a biographical grid paper (for the life-event data collection) administered face-to-face by specially trained interviewers, as well as a medical questionnaire completed by the team of the health services concerned. Statistical analyses adapted to longitudinal data will be used to study women's trajectories. The qualitative component consists of a survey by semi-structured interviews with women living with breast cancer and followed in the greater Paris area. These interviews are the subject of an audio recording and then a pseudonymized transcription. Thematic analyses will be carried out with a comprehensive approach that aims to analyze women's experiences. Perspectives and expected results This survey will provide scientific knowledge on the diagnosis, treatment and experience of breast cancer and its impact on the life trajectories of women born in France and sub-Saharan Africa. These results could thus contribute to the improvement of medical and psychosocial care for women living with breast cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer Female | Breast Neoplasm | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (2)
- label
- Women born in sub-Saharan Africa
- description
- Women born in sub-Saharan Africa and diagnosed with breast cancer
- label
- Women born in France
- description
- Women born in France and diagnosed with breast cancer
Primary outcomes (5)
- measure
- Circumstances of breast cancer diagnosis
- timeFrame
- From first signs until breast cancer diagnosis, up to 10 years
- description
- Proportion of women who declare, retrospectively, diagnosed following clinical signs, screening campaigns or medical prescription
- measure
- Time between date of arrival in France and breast cancer diagnosis
- timeFrame
- From arrival in France until the date of diagnosis, up to 10 years
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Women aged 18 or more * Women who consult in one of the partner hospitals of the study * For groups 1: women born in a country of sub-Saharan Africa * For group 2: women born in France * Have been diagnosed with breast cancer between the 1st of January 2014 and for more than three years at the time of the survey. Exclusion Criteria: * Does not speak French * Under 18 years old * Have been diagnosed with breast cancer before 2014 and for less than three years at the time of the survey.
References
Publications (3)
- BACKGROUNDAnne Gosselin, Karna Coulibaly, Joseph Larmarange, Clémence Schantz. Plan de gestion des données du projet SENOVIE France. Institut de Recherche pour le Développement (IRD). 2024. ⟨hal-04563793⟩
- BACKGROUNDLouise Ludet, Luis Teixeira, Gaëtan des Guetz, Clémence Schantz, for the SENOVIE group. Therapeutic mobility and breast cancer in France: Experiences of African women. SSM - Qualitative Research in Health, Volume 4, 2023. https://doi.org/10.1016/j.ssmqr.2023.100314.
- DERIVEDCoulibaly K, Schantz C, Teixeira L, Degrees du Lou A, Des Guetz G, Hocini H, Zelek L, Larmarange J, Gosselin A; SENOVIE study group; SENOVIE study group. A Life course approach to investigate breast cancer and migration in the greater Paris area: the SENOVIE study protocol. BMJ Open. 2025 Apr 2;15(4):e095759. doi: 10.1136/bmjopen-2024-095759. PMID 40180375